PMC:7161517 / 3366-3635 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T11","span":{"begin":49,"end":52},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T34","span":{"begin":245,"end":268},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T24","span":{"begin":197,"end":200},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T30","span":{"begin":49,"end":52},"obj":"Chemical"},{"id":"T31","span":{"begin":90,"end":104},"obj":"Chemical"},{"id":"T32","span":{"begin":94,"end":104},"obj":"Chemical"},{"id":"T33","span":{"begin":106,"end":120},"obj":"Chemical"},{"id":"T36","span":{"begin":106,"end":117},"obj":"Chemical"},{"id":"T37","span":{"begin":118,"end":120},"obj":"Chemical"},{"id":"T38","span":{"begin":151,"end":168},"obj":"Chemical"},{"id":"T39","span":{"begin":178,"end":189},"obj":"Chemical"}],"attributes":[{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A34","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A35","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_25354"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-sentences","denotations":[{"id":"T24","span":{"begin":0,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T6","span":{"begin":245,"end":268},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T98","span":{"begin":23,"end":37},"obj":"UBERON:0004535"},{"id":"T99","span":{"begin":94,"end":104},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T100","span":{"begin":106,"end":120},"obj":"CHEBI:48432;CHEBI:48432;DG_37"},{"id":"T101","span":{"begin":121,"end":138},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T102","span":{"begin":151,"end":168},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T103","span":{"begin":169,"end":189},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T104","span":{"begin":245,"end":259},"obj":"UBERON:0004535"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}

{"project":"LitCovid-PubTator","denotations":[{"id":"112","span":{"begin":90,"end":93},"obj":"Gene"},{"id":"113","span":{"begin":151,"end":177},"obj":"Gene"},{"id":"147","span":{"begin":245,"end":268},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"Gene:1636"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"Gene:4306"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Because of the adverse cardiovascular effects of RAS upregulation, its inhibition through ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) has been critical for the management of various cardiovascular diseases."}